Press release
Recurrent Glioblastoma Market to Grow Positively at a Paltry CAGR | Major players: Ascletis Pharmaceuticals, VAXIMM AG, VBL Therapeutics, OX2 Therapeutics, Erasca, Genexine, expected to boost the market
Recurrent Glioblastoma Market
Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Recurrent Glioblastoma Overview
Recurrent glioblastoma refers to the return or regrowth of glioblastoma multiforme (GBM), which is an aggressive type of cancer that begins in the brain. Despite initial treatment, which typically involves surgery followed by radiation and chemotherapy, glioblastomas tend to recur.
When glioblastoma recurs, it often does so within the original tumor site. However, it can also reappear in other areas of the brain. Recurrence may happen a few months or even years after the initial treatment. The management of recurrent glioblastoma poses significant challenges as it tends to be more aggressive and resistant to further treatment.
Several treatment options may be considered for recurrent glioblastoma, including:
Surgery: If the tumor is in a location that allows safe surgical removal, another surgery may be performed. However, it's often challenging due to the invasive nature of the tumor and risks associated with additional surgeries in the brain.
Radiation Therapy: Some patients might be eligible for further radiation therapy, especially with techniques like stereotactic radiosurgery, which delivers targeted radiation to the tumor while minimizing exposure to healthy tissues.
Chemotherapy: Different chemotherapy drugs or combination therapies may be used for recurrent glioblastoma. Temozolomide is one of the standard chemotherapy drugs used for this purpose.
Experimental Therapies: Clinical trials investigating new drugs, immunotherapies, targeted therapies, or other innovative treatment approaches might be available for patients with recurrent glioblastoma.
Palliative Care: In cases where curative treatments are not feasible, palliative care becomes essential. This type of care focuses on managing symptoms, improving the patient's quality of life, and providing support to the patient and their family.
Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Recent Breakthrough in the Recurrent Glioblastoma Market:
In January 2022, Ascletis Pharma announced the dosing of the first patient in the Phase III registration clinicaltrial of ASC40 combined with bevacizumab for treatment of recurrent Glioblastoma (rGBM).
In May 2021, Ascletis Pharma announced that China National Medical Products Administration (NMPAapproved the clinical trial application of ASC40 combined with bevacizumab to treat patients with recurrentGlioblastoma (rGBM) has been accepted for review by China NMPA.
Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Recurrent Glioblastoma Treatment Market
The Recurrent Glioblastoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Recurrent Glioblastoma market trends by analyzing the impact of current Recurrent Glioblastoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Recurrent Glioblastoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Recurrent Glioblastoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Recurrent Glioblastoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Promising Therapies in the Recurrent Glioblastoma Pipeline
ASC40 : Ascletis Pharmaceuticals
VXM01: VAXIMM AG
VB-111: VBL Therapeutics
hp1a8: OX2 Therapeutics
ERAS-801: Erasca
GX-I7: Genexine
Recurrent Glioblastoma Emerging Therapy Assessment
ASC40 : Ascletis Pharmaceuticals
ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novolipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumorcells by blocking de novo lipogenesis. Approximately 80% of 180 patients with recurrent Glioblastoma (rGBM)in the Phase III clinical trial are expected to be randomized and enrolled by the end of December 2022.Currently the product is in Phase III stage of development for the treatment of recurrent Glioblastoma.
Discover more about Recurrent Glioblastoma therapies in the pipeline, visit Recurrent Glioblastoma Drugs @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Leading Companies Working in the Recurrent Glioblastoma Market
Ascletis Pharmaceuticals
VAXIMM AG
VBL Therapeutics
OX2 Therapeutics
Erasca
Genexine
To understand key companies related to the Recurrent Glioblastoma Market, get a snapshot of the Recurrent Glioblastoma Regulatory and Patent Analysis @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Scope of the Recurrent Glioblastoma Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Recurrent Glioblastoma Companies: Ascletis Pharmaceuticals, VAXIMM AG, VBL Therapeutics, OX2 Therapeutics, Erasca, Genexine, and others
Key Recurrent Glioblastoma Pipeline Therapies: ASC40, VXM01, VB-111, hp1a8, ERAS-801, GX-I7, and others
Therapeutic Assessment: Recurrent Glioblastoma current marketed and emerging therapies
Recurrent Glioblastoma Market Dynamics: Recurrent Glioblastoma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Recurrent Glioblastoma Market Access and Reimbursement
Table of Contents
1. Recurrent Glioblastoma Market Key Insights
2. Recurrent Glioblastoma Market Report Introduction
3. Recurrent Glioblastoma Market Overview at a Glance
4. Recurrent Glioblastoma Market Executive Summary
5. Disease Background and Overview
6. Recurrent Glioblastoma Treatment and Management
7. Recurrent Glioblastoma Epidemiology and Patient Population
8. Patient Journey
9. Recurrent Glioblastoma Emerging Drugs
10. 7MM Recurrent Glioblastoma Market Analysis
11. Recurrent Glioblastoma Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Recurrent Glioblastoma Market Drivers
15. Recurrent Glioblastoma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Name: Kritika Rehani
E-mail: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Recurrent Glioblastoma Market to Grow Positively at a Paltry CAGR | Major players: Ascletis Pharmaceuticals, VAXIMM AG, VBL Therapeutics, OX2 Therapeutics, Erasca, Genexine, expected to boost the market here
News-ID: 3343420 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Glioblastoma
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…
Glioblastoma Treatment Drugs Market : Drivers, Restraint & Future Growth
Brain tumors is one of the leading cause of cancer which is common among children and teenagers. Glioblastoma (GBM) is most common grade four tumor, is malignant and contains dead tumor cells. It is also called as Glioblastoma multiforme, it has variants of giant cell Glioblastoma and gliosarcoma found in cerebral hemisphere of brain. The exact cause of this tumor is not known but is also found in spinal cord…
Glioblastoma Multiforme Treatment Market : Global Glioblastoma Multiforme Treatm …
Glioblastoma Multiforme Treatment Market
Precision Business Insights (PBI) in its report titled “Global Glioblastoma Multiforme Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
Glioblastoma multiforme is the high-grade glioma and…
Glioblastoma Multiforme Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial…
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging…
